Beyond the Standard Model: Neutrino Oscillations and the Search for New Physics

Fuente: Zenodo

Saved in:

Bibliographic Details
Main Author:	Hanamura, Satoshi
Format:	Recurso digital
Language:	English
Published:	Zenodo 2023
Subjects:	0-Sphere model
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Transition Theory of An Electron Traveling from Uncertain to Causal Basis
by: Hanamura, Satoshi
Published: (2019)

New horizons in the pharmacological management of venous thromboembolism
by: Andreas Verstraete, et al.
Published: (2025)

News on sickle cell disease: Heme‐driven disordered erythropoiesis
by: Francesca Vinchi
Published: (2024)

New approaches in gene therapy for sickle cell disease, moving in vivo
by: David G. Kent
Published: (2024)

Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Published: (2024)

Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smears
by: Tabita Ghete, et al.
Published: (2024)

Issue Information
Published: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
by: Raúl Córdoba, et al.
Published: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
by: Anna Ossami Saidy, et al.
Published: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
by: Enrico Attardi, et al.
Published: (2024)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
by: Henri C. Hupe, et al.
Published: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
by: Jan‐Niklas Eckardt, et al.
Published: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
by: Konstanze Döhner, et al.
Published: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
by: Harmony C. Ketchum, et al.
Published: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
by: Stephanie Sembill, et al.
Published: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
by: Uwe Platzbecker, et al.
Published: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
by: Sotiroula Chatzimatthaiou, et al.
Published: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
by: Elia Colin, et al.
Published: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Published: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
by: Daniel Mazza Matos
Published: (2026)

Publication Only
Published: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
by: Rebeqa Gunnarsson, et al.
Published: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
by: Mwanasha H. Merrill, et al.
Published: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
by: André Airosa Pardal, et al.
Published: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
by: Martijn W. C. Verbeek, et al.
Published: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
by: Suzana da Silva‐Benedito, et al.
Published: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
by: Thomas C. Wiemers, et al.
Published: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
by: Mira Kusterer, et al.
Published: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Published: (2025)

Issue Information
Published: (2024)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
by: Francesco Mannelli, et al.
Published: (2026)

Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
by: Konradin F. Müskens, et al.
Published: (2024)

Can health inequalities in sickle cell disease be addressed through novel therapies?
by: Stephen P. Hibbs, et al.
Published: (2025)

Issue Information
Published: (2024)

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
by: Shoshana Burke, et al.
Published: (2025)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
by: Romane Durand, et al.
Published: (2024)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
by: Marta Febo, et al.
Published: (2026)

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study
by: Marcus Hentrich, et al.
Published: (2024)